Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.660
-0.010 (-0.60%)
At close: Sep 17, 2025, 4:00 PM EDT
1.660
0.00 (0.00%)
After-hours: Sep 17, 2025, 4:10 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,318,111
Market Cap
185.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TLSA News
- 2 days ago - Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury - GlobeNewsWire
- 8 days ago - Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - GlobeNewsWire
- 12 days ago - Tiziana Life Sciences Announces Purchase of Shares by Chairman - GlobeNewsWire
- 4 weeks ago - Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy - GlobeNewsWire
- 5 weeks ago - FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient - GlobeNewsWire
- 3 months ago - Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting - Seeking Alpha
- 3 months ago - Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - GlobeNewsWire